MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
ZNTL Zentalis Pharmaceuticals
- 3.000
- +0.070+2.39%
Close Dec 20 16:00 ET
- 3.000
- 0.0000.00%
Post 20:01 ET
213.80MMarket Cap-1.20P/E (TTM)
3.100High2.890Low1.85MVolume2.900Open2.930Pre Close5.57MTurnover3.59%Turnover RatioLossP/E (Static)71.27MShares18.07052wk High0.60P/B154.86MFloat Cap2.66052wk Low--Dividend TTM51.62MShs Float87.190Historical High--Div YieldTTM7.17%Amplitude2.660Historical Low3.006Avg Price1Lot Size
About Zentalis Pharmaceuticals Company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Company Profile
SymbolZNTL
Company NameZentalis Pharmaceuticals
Listing DateApr 3, 2020
Issue Price18.00
Founded2014
CEOMs. Julie M. Eastland
MarketNASDAQ
Employees168
Fiscal Year Ends12-31
Address10275 Science Center Drive,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-263-4333
Websitehttp://www.zentalis.com
Company Executives
- Name
- Position
- Salary
- Julie M. Eastland
- Chief Executive Officer, President and Director
- --
- Andrea Paul
- Chief Legal Officer and Corporate Secretary
- 2.63M
- Dr. Kyle Rasbach, PhD,Pharm.D.
- Chief Business Officer
- --
- Dr. Diana F. Hausman, M.D.
- Chief Medical Officer
- 906.98K
- Dr. Mark Lackner, PhD
- Chief Scientific Officer
- --
- Vincent Vultaggio
- Principal Accounting Officer and Interim Principal Financial Officer
- --
- David M. Johnson
- Chairman of the Board
- 617.78K
- Scott D. Myers
- Chairman of the Board
- --
- Dr. Luke Nathaniel Walker, M.D.
- Director
- --
- Karan S. Takhar
- Independent Director
- --
- Dr. Jan Skvarka, PhD
- Independent Director
- 515.22K
- Dr. Enoch Kariuki, Pharm.D.
- Independent Director
- 516.97K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.